Nature Reviews Clinical Oncology

ISSN: 1759-4774

Journal Home

Journal Guideline

Nature Reviews Clinical Oncology Q1 Unclaimed

Nature Publishing Group United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

Nature Reviews Clinical Oncology is a journal indexed in SJR in Oncology with an H index of 198. It has an SJR impact factor of 14,809 and it has a best quartile of Q1. It has an SJR impact factor of 14,809.

Nature Reviews Clinical Oncology focuses its scope in these topics and keywords: biopsy, drug, cancer, trials, discovery, biomarkerdriven, clinical, standard, gameavoiding, era, ...

Type: Journal

Type of Copyright:


Open Access Policy:

Type of publications:

Publication frecuency: -

Scopus WOS
Categories: Oncology (Q1)

- €

Inmediate OA


Embargoed OA

- €

Non OA


Nature Reviews Clinical Oncology


SJR Impact factor


H Index


Total Docs (Last Year)


Total Docs (3 years)


Total Refs


Total Cites (3 years)


Citable Docs (3 years)


Cites/Doc (2 years)




No comments ... Be the first to comment!

Aims and Scope

biopsy, drug, cancer, trials, discovery, biomarkerdriven, clinical, standard, gameavoiding, era, glioblastomanivolumab, gvhddacomitinib, identifiedoesophageal, identifying, irradiation, liquid, lorlatinibfrom, fits, alikefrom, end, elderly, effective, combination, chemosensitivityrectal, chemoradiation, cells, cancerliquid, cancergenetics, breast, bloodtruly, biopsies,

Best articles by citations

Cetuximab's tip to become irresistible

View more

New scoring system for melanoma accurately stratifies risk

View more

G-CSF counteracts chemotherapy toxicity in neuroblastoma

View more

Palliative primary tumour resection in mCRC - debate continues

View more

FOLFIRI - improving toxicity in first-line treatment of advanced gastric cancer

View more

FOLFOXIRI - improving outcomes of metastatic colorectal cancer

View more

Erratum: Clinical trials of human papillomavirus vaccines and beyond

View more

NK gene donor selection in AML

View more

ALL: reducing cardiomyopathy

View more

Is androgen-deprivation therapy chosen wisely?

View more

CTCs - a predictive approach for targeted cancer therapy

View more

Heterogeneity of intermediate-stage HCC necessitates personalized management including surgery

View more

Gazing at the crystal ball of European radiotherapy

View more

Patients with brain metastases in early-phase trials

View more

Can less really be more in melanoma?

View more

Long-term response in high-risk CLL

View more

Treatment of aggressive lymphomas with anti-CD19 CAR T cells

View more

Is axillary lymph node clearance required in node-positive breast cancer?

View more

CONKO conquers

View more

PD-1 blockade: opening the door to attack

View more

Improving cancer detection rates

View more

Imatinib prior to allogeneic HSCT therapy improves both relapse and nonrelapse survival in patients with Ph+ALL

View more

Locoregional versus systemic therapy - robust positive data remain elusive

View more

BRAF and MEK inhibitors - good news comes in twos!

View more